0000899243-17-029466.txt : 20171222 0000899243-17-029466.hdr.sgml : 20171222 20171222161203 ACCESSION NUMBER: 0000899243-17-029466 CONFORMED SUBMISSION TYPE: 3/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20171211 FILED AS OF DATE: 20171222 DATE AS OF CHANGE: 20171222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Salyer Mark CENTRAL INDEX KEY: 0001725833 FILING VALUES: FORM TYPE: 3/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-21392 FILM NUMBER: 171272834 MAIL ADDRESS: STREET 1: C/O AMARIN PHARMA, INC. STREET 2: 1430 ROUTE 206, SUITE 200 CITY: BEDMINSTER STATE: NJ ZIP: 07921 FORMER NAME: FORMER CONFORMED NAME: Salyer Marc DATE OF NAME CHANGE: 20171219 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMARIN CORP PLC\UK CENTRAL INDEX KEY: 0000897448 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: FIRST FLOOR, BLOCK 3, THE OVAL, STREET 2: SHELBOURNE ROAD, BALLSBRIDGE CITY: DUBLIN STATE: L2 ZIP: 00000 BUSINESS PHONE: 353 1 6699 020 MAIL ADDRESS: STREET 1: FIRST FLOOR, BLOCK 3, THE OVAL, STREET 2: SHELBOURNE ROAD, BALLSBRIDGE CITY: DUBLIN STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: AMARIN PHARMACEUTICALS PLC DATE OF NAME CHANGE: 20000201 FORMER COMPANY: FORMER CONFORMED NAME: ETHICAL HOLDINGS PLC DATE OF NAME CHANGE: 19930322 3/A 1 doc3a.xml FORM 3/A SUBMISSION X0206 3/A 2017-12-11 2017-12-21 0 0000897448 AMARIN CORP PLC\UK AMRN 0001725833 Salyer Mark C/O AMARIN PHARMA, INC., 1430 ROUTE 206 BEDMINSTER NJ 07921 0 1 0 0 See Remarks Stock Option (Right to Buy) 3.49 2027-10-02 Ordinary Shares 700000 D On October 2, 2017, the reporting person was granted an option under the Amarin Corporation plc 2011 Stock Option Plan (the "Plan"). The option vests and becomes exercisable as follows: 25% of the total number of underlying shares shall vest on September 11, 2018, and the remaining 75% of the underlying shares shall vest ratably over the subsequent 36 months. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. This Form 3/A is being filed to correct the name of the Reporting Person on the prior Form 3 filing, which was filed on 12/21/2017. The prior Form 3 filing indicated that the name of the Reporting Person was "Marc Salyer." The correction is that the name of the Reporting Person is "Mark Salyer." There have been no other changes to the prior Form 3 filing. Title: Senior Vice President and Chief Commercial Officer In the event of a Change of Control (as defined in the Plan), the grant described in this Form 3 vests in full. /s/ Mark Salyer 2017-12-22 EX-24 2 attachment1.htm EX-24 DOCUMENT

                               POWER OF ATTORNEY
                          For Executing Forms 3, 4 and 5

     Know all by these presents, that the undersigned hereby constitutes and
appoints each of John F. Thero, Joseph T. Kennedy and Michael W. Kalb, each
acting singly, his true and lawful attorney-in-fact from the date hereof to:

     (1)  Execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer, director and/or 10% shareholder of Amarin Corporation
plc (the "Company"), forms and authentication documents for EDGAR Filing Access;

     (2)  execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer, director and/or 10% shareholder of the Company, Forms 3,
4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934
and the rules thereunder;

     (3)  do and perform any and all acts for and on behalf of the undersigned
that may be necessary or desirable to complete the execution of any such Form 3,
4 or 5, complete and execute any amendment or amendments thereto, and the timely
filing of such form with the United States Securities and Exchange Commission
and any other authority; and

     (4)  take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interests of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in his
discretion.

     The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform all and every act and thing whatsoever requisite,
necessary, and proper to be done in the exercise of any of the rights and powers
herein granted, as fully for all intents and purposes as the such attorney-in-
fact might or could do if personally present, with full power of substitution or
revocation, hereby ratifying and confirming all that such attorney-in-fact, or
his substitute or substitutes, shall lawfully do or cause to be done by virtue
of this power of attorney and the rights and powers herein granted.  The
undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, are not assuming any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended.

     This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

     By this Power of Attorney, the undersigned further revokes all previous
powers of attorney relating to the undersigned's obligations to file Forms 3, 4
and 5 in respect of the Company's securities under Section 16(a) of the
Securities Exchange Act of 1934 and related matters.

     IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed this 21st day of December, 2017.

                                         /s/ Mark Salyer
                                         ----------------------
                                         Mark Salyer